Immutep Ltd has released a press release.
Operational Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- TACTI-002 & INSIGHT-004 data to be presented at ASCO
- Immutep receives A$1,155,055 R&D Tax Incentive
- Immutep achieves Fast Track designation for Efti from US FDA
- Immutep announces European Patent Grant for LAG525
- Immutep collaborates with MSD for phase 2b head & neck trial
Later from Immutep
- Immutep granted Chinese patent for its LAG-3 candidate Efti
- Immutep enters New Collaboration with Merck KGaA for Efti
- Immutep granted European patent for its LAG-3 candidate Efti
- Immutep Reports Positive Data from its TACTI-002 ph 2 trial
- Immutep Reveals a New anti-LAG-3 Research Program
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep